Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30130383 | 0.85 | OPRM1 (0.56) | HPGDKEAP1KMT2ARAB9ANPC1 | |
| SCHEMBL812080 | 0.85 | OPRM1 (0.56) | HPGDKEAP1KMT2ARAB9ANPC1 | |
| SCHEMBL16870396 | 0.84 | KEAP1 (0.47) | HPGDKEAP1KMT2AALDH1A1TP53 | |
| SCHEMBL6645312 | 0.84 | KEAP1 (0.50) | HPGDKEAP1KMT2ARAB9ANPC1 | |
| SCHEMBL11000553 | 0.83 | KMT2A (0.49) | HPGDKEAP1KMT2ARAB9ANPC1 | |
| SCHEMBL3558867 | 0.83 | TSHR (0.47) | HPGDKEAP1KMT2AALDH1A1TP53 | |
| SCHEMBL8568150 | 0.81 | RAB9A (0.55) | HPGDKEAP1KMT2APOLBRAB9A | |
| SCHEMBL9194867 | 0.81 | KEAP1 (0.48) | HPGDKEAP1KMT2ARAB9ANPC1 | |
| SCHEMBL1436251 | 0.80 | RAB9A (0.54) | HPGDKMT2APOLBRAB9ANPC1 | |
| SCHEMBL30534176 | 0.80 | RAB9A (0.54) | HPGDKMT2APOLBRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150166500-A1 | Compounds and Methods for Catalytic Directed ortho Substitution of Aromatic Amides and Esters | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2015-06-18 | — | — | US | disclosed |
| US-20120302752-A1 | Compounds and Methods for Catalytic Directed ortho Substitution of Aromatic Amides and Esters | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2012-11-29 | — | — | US | disclosed |
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DARPHARMA, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | DARPHARMA, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | DARPHARMA, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DARPHARMA, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DARPHARMA, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1699450-A2 | CO-ADMINISTRATION OF DOPAMINE-RECEPTOR BINDING COMPOUNDS | Darpharma, INC. (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2006012640-A2 | METHOD OF ADMINISTRATION OF DOPAMINE RECEPTOR AGONISTS | DARPHARMA, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005062894-A2 | CO-ADMINISTRATION OF DOPAMINE-RECEPTOR BINDING COMPOUNDS | DARPHARMA, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-0845988-B1 | NOVEL FUSED ISOQUINOLINES AS DOPAMINE RECEPTOR LIGANDS | PURDUE RESEARCH FOUNDATION (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6194423-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | PURDUE RESEARCH FOUNDATION | 2001-02-27 | — | — | US | disclosed |
| US-5959110-A | SUBSTITUTED TETRAHYDRO-1H-NAPH(1,2,3-DE)ISOQUINOLINE COMPOUND USEFUL FOR TREATING NERVOUS SYSTEM DISORDERS | PURDUE RESEARCH FOUNDATION (US) | 1999-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DRD2, DRD1, DRD3 | HPGD 1821/4885KEAP1 3249/4885KMT2A 2426/4885 |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | ADRA1D, DRD2, CHRM3 | HPGD 604/4885KEAP1 1354/4885KMT2A 3199/4885 |
| US-20150166500-A1 | Compounds and Methods for Catalytic Directed ortho Substitution of Aromatic Amides and Esters | DDC, AOC2, AOC3 | HPGD 2168/4885KEAP1 862/4885KMT2A 1382/4885 |
| US-20120302752-A1 | Compounds and Methods for Catalytic Directed ortho Substitution of Aromatic Amides and Esters | DDC, AOC2, AOC3 | HPGD 2168/4885KEAP1 862/4885KMT2A 1382/4885 |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DRD2, DRD1, DRD3 | HPGD 1804/4885KEAP1 3245/4885KMT2A 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.